Protease inhibitor combinations: a breakthrough in treating HIV infection Larry PrescottGill Higgins Newsletter Article 05 February 2013 Pages: 3 - 4
Periconceptional vitamin intake: why, which and how much? Newsletter Article 05 February 2013 Pages: 5 - 5
Improvement needed in use of HMG CoA reductase inhibitors Newsletter Article 05 February 2013 Pages: 5 - 5
Switching between cyclosporin formulations not without risk Newsletter Article 05 February 2013 Pages: 5 - 5
Opportunity to optimise stroke prophylaxis in elderly with AF Newsletter Article 05 February 2013 Pages: 6 - 6
Evidence that appropriate-use programmes cut costs Kathleen McConnell Newsletter Article 05 February 2013 Pages: 7 - 8
A headache on the horizon for sumatriptan? Sandra MacPherson Newsletter Article 05 February 2013 Pages: 11 - 12
Paclitaxel + carboplatin promising in ovarian carcinoma Newsletter Article 05 February 2013 Pages: 13 - 13
LMWH prophylaxis of ‘little benefit’ in patient subgroup Newsletter Article 05 February 2013 Pages: 13 - 13
Tailoring of antineoplastic therapy in breast cancer? Newsletter Article 05 February 2013 Pages: 14 - 14
Prochlorperazine better than metoclopramide for migraine Newsletter Article 05 February 2013 Pages: 16 - 16
Didanosine + hydroxycarbamide = undetectable HIV levels … Newsletter Article 05 February 2013 Pages: 17 - 17
… and place for didanosine when zidovudine inappropriate Newsletter Article 05 February 2013 Pages: 17 - 17
Radionuclide GFR assessments useful for carboplatin dosing Newsletter Article 05 February 2013 Pages: 20 - 20
Peripheral nerve disorders associated with fluoroquinolones Newsletter Article 05 February 2013 Pages: 21 - 21
In utero anticonvulsant exposure and neurological disorders Newsletter Article 05 February 2013 Pages: 21 - 21
Calcium antagonists may affect psychomotor performance Newsletter Article 05 February 2013 Pages: 21 - 21